Antibodies targeting other immune checkpoints, such as programmed cell death-1 (PD-1) and its ligand (PD-L1), now have multiple approvals in patients with NSCLC, CRC, and other cancers [20, 21]. This evidence concerns the gene PDCD1 and colorectal carcinoma.